Dr. LeonardiThe ongoing rush of safe, highly effective systemic agents for psoriasis has created a new era in which substantial numbers of patients may achieve complete clearance, said an expert at the American Academy of Dermatology 75th Annual Meeting, held here.
In the year 2000, said Craig Leonardi, M.D., two authors called complete skin clearance an unrealistic expectation for patients with psoriasis.1
The fact is that right now, we have many drugs that are so far different from what we used to use even five years ago that complete clearance is a realistic possibility in many of our patients, says Dr. Leonardi. He is adjunct professor of dermatology at St. Louis University and a St. Louis, Missouri-based dermatologist in private practice.
As a reference point, he says, Finally, we have numbers for how methotrexate performs in modern measurement systems. In a well-designed 120-patient trial with modest dose escalation, 41% of patients achieved psoriasis area and severity index (PASI) 75, and 66% achieved PASI 50 at week 16.2 This settles the issue of how well methotrexate indeed performs, Dr. Leonardi says. Although no study patients developed pancytopenia, Its always an issue in the back of my mind. At any one time Ill have hundreds of patients on methotrexate. Based on research in rheumatoid arthritis, he says, risk factors include renal disease, hypoalbuminemia, infection, age and concomitant medication use.
New targets
Since the demise of T-cell inhibitors such as alefacept and efalizumab, Dr. Leonardi says, Weve been concentrating on cytokines and cytokine inhibitors. And its been a very busy time in the pharmaceutical industry and for those of us who do this research.
Among tumor necrosis factor alpha (TNFa) inhibitors that dermatologists may not have heard much about, Certolizumab is one you should definitely remember. It is a pegylated TNF-alpha inhibitor, not a monoclonal antibody. In trials, it is a high-performance skin-clearing drug. In phase 3 testing, 81% and 82% in separate cohorts achieved PASI 75.3 Thats functionally equivalent to infliximab. This is a drug you might be able to reach for. You can prescribe it currently for psoriatic arthritis its approved. And based on phase 3 results in psoriasis, We expect it to sail through the approval process.
Recent approvals in the TNF inhibitor category include biosimilar versions of infliximab, etanercept and adalimumab. And there are others in the pipeline.
New indications for existing drugs include hidradenitis suppurativa and uveitis (adalimumab) and pediatric psoriasis (etanercept). Physicians use golimumab mainly for psoriatic and rheumatoid arthritis, he says. It offers very modest results in psoriasis.
We know that psoriasis is a significant cardiovascular risk factor. Patients with severe psoriasis have a marked increased relative risk of myocardial infarction (MI) compared to mild psoriasis4 and, in another analysis, control subjects.
More recently, research analyzing cardiovascular risk in various treatment groups has shown that TNF inhibitors and methotrexate reduce risk of MI around 50%.5 This is the first time we are seeing evidence that treatments can reduce the risk of myocardial infarction, Dr. Leonardi says.
Additionally, an analysis of cardiovascular risk in patients on TNF inhibitors showed a statistically significant, marked decrease of MI risk, starting at around month 12 and lasting several months thereafter, versus patients on methotrexate.6 Even more amazing, cumulative use of TNF antagonists serially reduced the risk of myocardial infarction. Predicted hazard rate reductions at one, two and three years were 21%, 38% and 51%. And theres probably more to be gained beyond three years. What a wonderful story. Were treating their skin and joints and giving them an increased benefit from a cardiovascular risk perspective, he says.
Among interleukin (IL)-23 inhibitors, he says, a straightforward phase 3 study of tildrakizumab (two doses, versus placebo or etanercept) showed that the higher dose outperforms the lower dose 66% versus 61% in terms of both PASI 75 and physician assessments, without noteworthy safety issues.7 With regard to severe infections, malignancies, major adverse cardiovascular events and drug hypersensitivity reactions, all of these issues are comparable to placebo or to etanercept. This drug appears to be safe and well tolerated.
The phase 3 study of guselkumab did not even consider PASI 75 a primary endpoint, Dr. Leonardi says. Rather, 73% of patients reached PASI 90 at 16 weeks, versus 2.9% of placebo-treated patients.8 This is a significant drug. It distinguishes itself quite clearly from adalimumab in terms of efficacy, with comparable safety findings.
In phase 2 testing, a single dose of risankizumab allowed 87% of patients to reach PASI 75, and 58% to reach PASI 90, at 12 weeks.9 And one-third of these patients remained clear for more than 66 weeks. James Krueger, M.D., Ph.D., has called the drug and immunologic disruptor, says Dr. Leonardi, because its pharmacodynamic effect far exceeds its pharmacokinetic effect. Dr. Krueger is D. Martin Carter Professor in Clinical Investigation at Rockefeller University.
IL-17 inhibitors
In secukinumab four-year data, Efficacy whether its PASI 75 (88.5%), PASI 90 (66.4%) or PASI 100 (43.5%) seems to be maintained.10 The caveat is that this is an as-observed analysis. In other words, the denominator is dropping over time as patients achieving lesser efficacy and tolerability drop out. For most patients, Its not surprising that the efficacy should seem stable over time. It would have been a real problem if we saw efficacy dropping off. Regarding serious adverse events, he adds, There are a lot of zeros in the table, including for Crohns disease. There were two cases of ulcerative colitis. This issue of ulcerative colitis and its association with IL-17 antagonists is ongoing, and were going to have to see how that plays out. Its a rare event less than one in 1000 patients in the secukinumab data.
Unpublished five-year data for ixekizumab, in an analysis which accounted for dropouts over time, shows stable PASI 75, 90 and 100 results (approximately 80%, 70% and 47%, respectively), he says. As for AEs that led to drug discontinuation (13), There were many one-off events that dont seem to have any pattern. All adverse events also appear uncommon and stable over time, he added.
The IL-17 receptor antagonist brodalimumab showed efficacy similar to that of ixekizumab in phase 3 trials (86%/85% PASI75, and 37%/44% PASI 100).11 But early in these trials, he says, concerns for depression, suicidal ideation and behavior appeared. There were six suicides in these trials four in the skin trials and two in psoriatic arthritis trials. The FDA remarked that this was an unprecedented collection of serious issues for any psoriasis trial to date. I would take that to heart.
Amgen abandoned the products development in 2015, and Valeant took it to an FDA hearing in July 2016, at which all 18 FDA reviewers recommended approval although 14 advised implementing a strong risk management program. So this drug has a boxed warning for depression and suicide coming out of the gate, and a risk-management system reminiscent of iPLEDGE, he said.
We must wait and see how our specialty reacts to this, how onerous this will be in our offices and whether or not this drug will gain any traction given that equally efficacious drugs with fewer hassles already exist. Moreover, Dr. Leonardi noted that patients with psoriasis have elevated baseline levels of suicidal ideation and depression versus the general population.12
Development of tofacitinib in dermatology has stopped, said Dr. Leonardi. The FDA has returned the application to Pfizer. The problem with this drug is that patients needed a big dose 15 mg twice a day to have outstanding efficacy. But there was a hard safety signal that occurred much earlier at lower doses. FDA officials noted that in rheumatoid arthritis trials, 14 of the 15 patients who died were on tofacitinib. And there were 34 opportunistic infections, he added, all in tofacitinib-treated patients. In the psoriasis trials, there were more than 1,000 cases of herpes zoster.
However, he said, tofacitinib can be useful off-label for indications including alopecia areata, alopecia-associated nail dystrophy, vitiligo and severe atopic dermatitis. When he prescribed 5 mg of tofacitinib twice-daily for a patient with a 15-year history of alopecia universalis and steroid induced adrenal suppression, One year later, she had more hair than I did.
Disclosures: Dr. Leonardi has been a consultant, researcher and/or speaker for Abbvie, Amgen, Celgene, Coherus, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, Leo, Merck, Merck-Serono, Novartis, Pfizer, Sandoz and Vitae. He also provides phototherapy and has an infusion center.
References
1. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol. 2000;42(5 Pt 1):796-802.
2. Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10068):528-537.
3. http://www.ucb.com/stories-media/press-releases/article/CIMZIA-certolizu... http://www.ucb.com/stories-media/press-releases/article/CIMZIA-certolizu.... Published October 3, 2016. Accessed April 7, 2017.
4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-41.
5. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244-50.
6. Wu JJ, Gurin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor- inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81-90.
7. Reich K, et al. Tildrakizumab, selective IL-23p19 antibody, in the treatment of chronic plaque psoriasis: results from two randomized, controlled, Phase 3 trials (reSURFACE 1 and reSURFACE 2) [abstract]. Presented as a late breaking abstract at the European Academy of Dermatology and Venereology 2016. October 1, 2016.
8. Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417.
9. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebocontrolled trial. J Allergy Clin Immunol. 2015;136(1):116124; e117. 29.
10. Bissonnette R, et al. Secukinumab maintains high levels of efficacy through 4 years of treatments: Results from an extension to a phase 3 study (SCULPTURE). Paper presented at: European Academy of Dermatology and Venereology Annual Meeting.; October 01, 2016; Vienna, Austria.
11. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-28.
12. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol. 1993;32(3):188-90.
Visit link:
New systemic psoriasis treatments keep raising bar - ModernMedicine
- Why Jews With Psoriasis Might Think Twice About Seeking Treatment in Jordan - December 20th, 2013 [December 20th, 2013]
- Skin conditions leave emotional scars - December 20th, 2013 [December 20th, 2013]
- Psoriasis Free Forever Review | How This Program Helps People Treat The Root Causes Of Their Psoriasis Symptoms ... - December 20th, 2013 [December 20th, 2013]
- Psoriasis | University of Maryland Medical Center - December 20th, 2013 [December 20th, 2013]
- Psoriasis Treatment, Symptoms, Pictures, Types, Prognosis ... - December 20th, 2013 [December 20th, 2013]
- Psoriasis - National Library of Medicine - PubMed Health - December 20th, 2013 [December 20th, 2013]
- Psoriasis: MedlinePlus - U.S. National Library of Medicine - December 20th, 2013 [December 20th, 2013]
- Psoriasis - Wikipedia, the free encyclopedia - December 20th, 2013 [December 20th, 2013]
- Psoriasis Symptoms, Treatment, Causes, Medication Information ... - December 21st, 2013 [December 21st, 2013]
- Psoriasis Free For Life Review - Watch This Before You Buy - Video - December 21st, 2013 [December 21st, 2013]
- Natural Psoriasis Relief in Seattle, Washington - Video - December 21st, 2013 [December 21st, 2013]
- PSORIASIS VULGARIS - Video - December 21st, 2013 [December 21st, 2013]
- Top 5 Powerful Home Remedies For Psoriasis - Video - December 21st, 2013 [December 21st, 2013]
- Psoriasis feedback after hijama - Video - December 21st, 2013 [December 21st, 2013]
- 9 Home Remedies For Scalp Psoriasis - Video - December 22nd, 2013 [December 22nd, 2013]
- Manga - Psoriasis - Video - December 22nd, 2013 [December 22nd, 2013]
- How to treat psoriasis | In Good Shape - Interview - Video - December 22nd, 2013 [December 22nd, 2013]
- Best Scalp Psoriasis Treatment - Video - December 22nd, 2013 [December 22nd, 2013]
- Sandoz begins Phase III clinical trial for biosimilar adalimumab - December 23rd, 2013 [December 23rd, 2013]
- Psoriasis - Wikipedia, la enciclopedia libre - December 23rd, 2013 [December 23rd, 2013]
- What Is Psoriasis? - December 23rd, 2013 [December 23rd, 2013]
- Psoriasis Treatment Medical Course - Video - December 23rd, 2013 [December 23rd, 2013]
- Healing Psoriasis Hypnosis Session - Video - December 23rd, 2013 [December 23rd, 2013]
- Natural Farm cure for Skin Problems like Psoriasis - Video - December 26th, 2013 [December 26th, 2013]
- Psoriasis - 100% Natural Treatment Shivax® - December 27th, 2013 [December 27th, 2013]
- Psoriasis Symptoms, Causes, Treatment - What is psoriasis ... - December 28th, 2013 [December 28th, 2013]
- 79 PSORIASIS SYMPTOMS HOMEOPATHY TREATMENT K N SRIDHAR P3 - Video - December 28th, 2013 [December 28th, 2013]
- 79 PSORIASIS SYMPTOMS HOMEOPATHY TREATMENT K N SRIDHAR P2 - Video - December 28th, 2013 [December 28th, 2013]
- 79 PSORIASIS SYMPTOMS HOMEOPATHY TREATMENT K N SRIDHAR P1 - Video - December 28th, 2013 [December 28th, 2013]
- Can Acupuncture treat psoriasis and other scalp disorders? - Video - December 28th, 2013 [December 28th, 2013]
- Psoriasis - Wikipédia - December 31st, 2013 [December 31st, 2013]
- Psoriatic nails - Wikipedia, the free encyclopedia - December 31st, 2013 [December 31st, 2013]
- How to Cure Psoriasis - Psoriasis Symptoms, Treatment, Causes, Medication Information - Video - December 31st, 2013 [December 31st, 2013]
- Psoriasis Chronicles - Dealing with Depression, Anxiety and Anger - Video - January 2nd, 2014 [January 2nd, 2014]
- How to Prevent Psoriasis Flare-Ups - January 4th, 2014 [January 4th, 2014]
- Psoriasis Treatment | Health Plus | Studio N - Video - January 4th, 2014 [January 4th, 2014]
- Ayurvedic Remedy for Psoriasis - By Panditha Elchuri - Video - January 4th, 2014 [January 4th, 2014]
- Silica Gel For Psoriasis / Neurodermatitis - Video - January 4th, 2014 [January 4th, 2014]
- comment traiter son psoriasis détail oubliés - Video - January 4th, 2014 [January 4th, 2014]
- Psoriasis tends to relapse after stopping Methotrexate, shown in a case at Life Force - Video - January 4th, 2014 [January 4th, 2014]
- hiking nevada Health and Wellness Enthusiast Dawn Talks About Managing Plaque Psoriasis hiking watch - Video - January 5th, 2014 [January 5th, 2014]
- Guttate psoriasis - Wikipedia, the free encyclopedia - January 7th, 2014 [January 7th, 2014]
- Biofeedback May Help Control Stress-Related Diseases - January 8th, 2014 [January 8th, 2014]
- Psoriasis can be managed with proper treatment - January 10th, 2014 [January 10th, 2014]
- CNN anchor: How I fight psoriasis - January 10th, 2014 [January 10th, 2014]
- Psoriasis - My Home Remedies - January 10th, 2014 [January 10th, 2014]
- Psoriasis: MedlinePlus en español - January 10th, 2014 [January 10th, 2014]
- Psoriatic arthritis - Wikipedia, the free encyclopedia - January 10th, 2014 [January 10th, 2014]
- CNN anchor Zain Verjee: How I fight psoriasis - January 11th, 2014 [January 11th, 2014]
- Testimonio psoriasis - Video - January 14th, 2014 [January 14th, 2014]
- Heroin addict with severe Psoriasis - Video - January 15th, 2014 [January 15th, 2014]
- biospray for Psoriasis - Video - January 15th, 2014 [January 15th, 2014]
- Psoriasis - Psoriasis Free For Life - Video - January 15th, 2014 [January 15th, 2014]
- 8 Cure For Scalp Psoriasis - Video - January 15th, 2014 [January 15th, 2014]
- Learn about plaque psoriasis, guttate psoriasis, inverse ... - January 16th, 2014 [January 16th, 2014]
- Psoriasis - Symptoms, Triggers, and Causes of Psoriasis on WebMD - January 16th, 2014 [January 16th, 2014]
- Psoriasis Causes, Symptoms, Treatments, Home Remedies - January 16th, 2014 [January 16th, 2014]
- Psoriasis Treatment - Dermasis Psoriasis Cream - My Honest Review - Video - January 16th, 2014 [January 16th, 2014]
- TV Commercial Psoriasis Speaks Couple Looking At Rings In Jewelery Store Emotional - Video - January 16th, 2014 [January 16th, 2014]
- TV Commercial Humira Psoriasis Medication Salon Clearer Skin is Possible - Video - January 16th, 2014 [January 16th, 2014]
- Psoriasis Symptoms, Causes and Treatment Pictures Slideshow - Video - January 16th, 2014 [January 16th, 2014]
- Psoriasis - Medscape Reference - January 19th, 2014 [January 19th, 2014]
- 5 Home Remedies For Scalp Psoriasis - Video - January 19th, 2014 [January 19th, 2014]
- Ikonsulta Mo: Medical Advise on Psoriasis - Video - January 19th, 2014 [January 19th, 2014]
- Patient Recruitment: Television Campaign for Severe Psoriasis - Video - January 23rd, 2014 [January 23rd, 2014]
- Patient Recruitment: Television Campaign for resistant, summertime Mild to Moderate Psoriasis - Video - January 23rd, 2014 [January 23rd, 2014]
- Dr stephen ferguson ND PhD chronic fatigue psoriasis cured - Video - January 23rd, 2014 [January 23rd, 2014]
- Noir Naturals Age of Innocence (Unscented) Goat's Milk Lotion for Psoriasis Relief - Video - January 23rd, 2014 [January 23rd, 2014]
- New biologic drugs offer relief for psoriasis sufferers - January 24th, 2014 [January 24th, 2014]
- Psoriasis traitement appliquer le lait pour le corps ISO UREA MD Vidéo La Roche Posay INFO PSO - Video - January 24th, 2014 [January 24th, 2014]
- Psoriasis - Video - January 24th, 2014 [January 24th, 2014]
- Coping with psoriasis - Video - January 26th, 2014 [January 26th, 2014]
- Exfoliative Dermatitis/Psoriasis Vulgaris with Psoriatic Arthritis with English Subtitles - Video - January 26th, 2014 [January 26th, 2014]
- Psoriasis skin care routine 2014 - Video - January 27th, 2014 [January 27th, 2014]
- How to treat psoriasis effectively - By Franziska Ringpfeil, Board Certified Dermatologist - Video - January 28th, 2014 [January 28th, 2014]
- My Psoriasis 411: Apple Cider Vinegar Tutorial for Scalp Treatment - Video - January 29th, 2014 [January 29th, 2014]
- 12 Best and Worst Foods for Psoriasis - January 31st, 2014 [January 31st, 2014]
- Psocial Psoriasis en radio Tagoror - Video - January 31st, 2014 [January 31st, 2014]
- Psocial Psoriasis en Canarias Hoy - Video - January 31st, 2014 [January 31st, 2014]
- Psoriasis Natural Treatment that Workswww savevid com - Video - January 31st, 2014 [January 31st, 2014]